Access Pharmaceuticals to Report New MuGard Clinical Trial Data Thursday at the MASCC/ISOO Symposium in New York City

Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City (via PR Newswire)

DALLAS and NEW YORK, June 26, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, today announced that the results of a recent…

---

 

Intellipharmaceutics International @ The Next Biggest Winner - $IPCI

The Next Biggest Winner helps both savvy and novice investors find the next biggest winning stock. In this interview, Shameze Rampertab of Intellipharmaceutics International (NASDAQ: IPCI) reports on the company and its progress. Mr. Rampertab joined Intellipharmaceutics in November 2010. He is a chartered accountant (CA) since 1994, brings public company experience to Intellipharmaceutics, having previously served as the Director, Finance and Secretary-Treasurer for then-public Drug Royalty Corp. Mr. Rampertab also served as health sciences and biotechnology analyst at several investment banking firms including Canaccord Capital, and was until recently a Partner, Healthcare Investment Banking at Loewen Ondaatje McCutcheon Limited, where he specialized in raising equity funds for life-science companies. He received an MBA from McMaster University and a BSc. from the University of Toronto and has substantial expertise with licensing and royalty deals. Mr. Rampertab is currently Chairman of the Board of Imaging Dynamics Company Ltd. (TSX: IDL).

Intellipharmaceutics is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix(TM) technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of product candidates in various stages of development, including six ANDAs under review by the FDA, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes, pain and infection.

Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City (ACCP)

Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation platinum chemotherapeutic drug and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas. 

The Company has announced that it will be presenting at a joint international symposium of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) on Supportive Care in Cancer, in which the results of a recent interim analysis of data from an ongoing MuGard clinical trial will be shared.

On Thursday June 28th, a podium presentation will be made by one of the lead investigators in the study, and on Friday June 29th results will be presented in a poster on display. In addition to these presentations, "Access will have its MuGard booth in the commercial exhibit hall to educate the attendees on the clinical benefit MuGard offers patients undergoing cancer treatment. The annual MASCC/ISOO Symposium is the preeminent international conference to focus on supportive care in oncology and will be held this week at the Hilton New York Hotel on Thursday, June 28th – Saturday, June 30th."

Read more at PRNewswire.com. 

Coronado Biosciences Added to Russell 3000(R) Index

Coronado Biosciences, Inc., (CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, announced today the Company has been added to the Russell Global, Russell 3000(R) and Russell Microcap(R) Indexes following the reconstitution of the Russell's U.S. and global equity indexes.

"We are excited to be included in the Russell 3000(R) Index," said Dr. Bobby W. Sandage, Jr., Coronado's President and CEO. "We believe that our addition to the Index will increase the visibility of our Company to a broader range of potential investors."

Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000(R) Index and Russell Microcap Index. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000(R) Index or small-cap Russell 2000(R) Index as well as the appropriate growth and value style indexes. The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. In the institutional marketplace, an industry-leading $3.9 trillion in assets currently are benchmarked to them. Russell calculates more than 80,000 benchmarks daily covering approximately 98 percent of the investable market globally, 83 countries and more than 10,000 securities. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Investor Relations
Lucy Lu, MD, Executive Vice President
& Chief Financial Officer
Coronado Biosciences, Inc.
781-238-6619; ir@coronadobio.com
Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com
Media Relations
Dennis S. Dobson Jr., CEO
Dobson Media Group
203-258-0159; dobsonpr@erols.com

Intellipharmaceutics International (NASDAQ: IPCI) @ Seeking Alpha's "Bio Pharma Momentum Movers List"

Intellipharmaceutics International (NASDAQ: IPCI) was listed yesterday on Seeking Alpha's "Bio Pharma Momentum Movers List", and the stock closed up almost 5% yesterday:

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

View the full IPCI chart at Wikinvest

IPCI is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix(TM) technologies are a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of product candidates in various stages of development, including six ANDAs under review by the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes, pain and infection.

Tonix Pharmaceuticals @ Marcum MicroCap Conference (TNXP) - video

Tonix Pharmaceuticals (OTC BB: TNXP) presentation at the 2012 Marcum Microcap Conference was webcast, and the video of the presentation is below.

Video streaming by Ustream

TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX’s core technology improves the quality of sleep in patients with chronic pain syndromes. TONIX’s lead products are designed to be fundamental advances in sleep hygiene and pain management and to be safer and more effective than currently available treatments. TONIX’s products are the result of a program to harvest advances in science and medicine to search for potential therapeutic solutions among known pharmaceutical agents. TONIX is developing new formulations that have been optimized for new therapeutic uses. Its most advanced product candidates, TNX-102 for fibromyalgia and TNX-105 for post-traumatic stress disorder, are novel dosage formulations of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. To learn more about the Company and its pipeline of treatments for central nervous system conditions,

Medgenics' Orphan Drug Approval For Hepatitis Therapy @ Seeking Alpha - $MDGN

"Big Pharma Target"

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) is a clinical-stage biopharmaceutical company developing an innovative and proprietary platform technology - a biological "Biopump" - which allows patients to produce, within their bodies and on a long-term basis, their own natural human protein therapy for the treatment of a range of chronic diseases, such as anemia and hepatitis C.

Over on Seeking Alpha, drugs to treat the hepatitis virus are seen as "becoming the hottest area of medicine." The article goes on to state:

"No wonder that large biotechs are looking to buy - hepatitis viruses, grouped as A, B, C, and D, are considered a worldwide epidemic and highly contagious. The World Health Organization (WHO) puts the number of those infected at 550 million, or nearly 8% of the entire human population. Almost 70% of people advance to a chronic state. It is the number one reason for liver cancer. There is no cure.

Which brings us to - Medgenics (MDGN) announcing an Orphan Drug Designation for its INFRADURE for the treatment of hepatitis D. Orphan Drug Designation means smaller clinical trials and faster approval time.

This announcement follows an astounding run of good news for Medgenics including FDA approval of an Investigational New Drug (IND) application for its EPODURE device for anemia and the launch of a US-based manufacturing facility for its Biopump, the company, making good on our prediction of a highly-favorable relationship with the FDA.

Also, good results would pave the way for hepatitis C trials in the US and for final approval for hepatitis D in Israel. Hepatitis D affects 15 million people worldwide. Hepatitis C is a larger market at 180 million, and we envision INFRADURE serving as a platform technology to launch all versions of treatment for the hepatitis virus."

Medgenics was also featured on the Seeking Alpha's Bio Pharma Movers List.

Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day (KERX)

Keryx Biopharmaceuticals (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

The Company has announced that its upcoming Analyst Day will be webcast live on Thursday, June 21, 2012 at 4:30 pm ET. Scheduled speakers include the following:

• Julia Lewis, M.D. will provide her perspective on the Zerenex (ferric citrate) Phase 3 clinical program and the potential Zerenex product profile.-- Professor of Medicine, Division of Nephrology, Vanderbilt University School of Medicine
• Geoffrey Block, M.D. will discuss the potential for Zerenex in pre-dialysis.-- Director of Research, Denver Nephrology and Associate Clinical Professor in Medicine, University of Colorado Health Sciences Center
• David Goldfarb, M.D. will discuss the potential importance of citrate.-- Chief, Nephrology Division, NY Campus of NY Harbor Health Care Veterans Affairs System and Professor of Medicine & Physiology, NYU School of Medicine.

To access the live audio webcast, please visit the Company's Investor Relations section of their website ( http://investors.keryx.com ). An archived version of the webcast will become available following the conclusion of the live presentation.